170 related articles for article (PubMed ID: 7552334)
1. Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease.
Maneuf YP; Mitchell IJ; Crossman AR; Woodruff GN; Brotchie JM
Brain Res; 1995 Jun; 683(1):102-8. PubMed ID: 7552334
[TBL] [Abstract][Full Text] [Related]
2. Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism.
Hughes NR; McKnight AT; Woodruff GN; Hill MP; Crossman AR; Brotchie JM
Mov Disord; 1998 Mar; 13(2):228-33. PubMed ID: 9539334
[TBL] [Abstract][Full Text] [Related]
3. The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat.
Hill MP; Brotchie JM
Br J Pharmacol; 1999 Dec; 128(7):1577-85. PubMed ID: 10602339
[TBL] [Abstract][Full Text] [Related]
4. Modulation of glutamate release by a kappa-opioid receptor agonist in rodent and primate striatum.
Hill MP; Brotchie JM
Eur J Pharmacol; 1995 Jul; 281(1):R1-R2. PubMed ID: 8566106
[TBL] [Abstract][Full Text] [Related]
5. Control of glutamate release by calcium channels and kappa-opioid receptors in rodent and primate striatum.
Hill MP; Brotchie JM
Br J Pharmacol; 1999 May; 127(1):275-83. PubMed ID: 10369483
[TBL] [Abstract][Full Text] [Related]
6. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
Greenamyre JT; Eller RV; Zhang Z; Ovadia A; Kurlan R; Gash DM
Ann Neurol; 1994 Jun; 35(6):655-61. PubMed ID: 8210221
[TBL] [Abstract][Full Text] [Related]
7. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus.
Maneuf YP; Mitchell IJ; Crossman AR; Brotchie JM
Exp Neurol; 1994 Jan; 125(1):65-71. PubMed ID: 8307125
[TBL] [Abstract][Full Text] [Related]
8. Activation of metabotropic glutamate receptor 1 inhibits glutamatergic transmission in the substantia nigra pars reticulata.
Wittmann M; Hubert GW; Smith Y; Conn PJ
Neuroscience; 2001; 105(4):881-9. PubMed ID: 11530226
[TBL] [Abstract][Full Text] [Related]
9. Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease.
Ochi M; Shiozaki S; Kase H
Neuroscience; 2004; 127(1):223-31. PubMed ID: 15219684
[TBL] [Abstract][Full Text] [Related]
10. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism.
Bergman H; Wichmann T; Karmon B; DeLong MR
J Neurophysiol; 1994 Aug; 72(2):507-20. PubMed ID: 7983515
[TBL] [Abstract][Full Text] [Related]
11. Fos expression following activation of the ventral pallidum in normal rats and in a model of Parkinson's Disease: implications for limbic system and basal ganglia interactions.
Turner MS; Gray TS; Mickiewicz AL; Napier TC
Brain Struct Funct; 2008 Sep; 213(1-2):197-213. PubMed ID: 18663473
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of metabotropic glutamate receptor 1alpha in globus pallidus and substantia nigra of parkinsonian monkeys.
Kaneda K; Tachibana Y; Imanishi M; Kita H; Shigemoto R; Nambu A; Takada M
Eur J Neurosci; 2005 Dec; 22(12):3241-54. PubMed ID: 16367790
[TBL] [Abstract][Full Text] [Related]
13. Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata.
Broadstock M; Austin PJ; Betts MJ; Duty S
Br J Pharmacol; 2012 Feb; 165(4b):1034-45. PubMed ID: 21627638
[TBL] [Abstract][Full Text] [Related]
14. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets.
Lastres-Becker I; Cebeira M; de Ceballos ML; Zeng BY; Jenner P; Ramos JA; Fernández-Ruiz JJ
Eur J Neurosci; 2001 Dec; 14(11):1827-32. PubMed ID: 11860478
[TBL] [Abstract][Full Text] [Related]
15. Dynorphin exerts both postsynaptic and presynaptic effects in the Globus pallidus of the rat.
Ogura M; Kita H
J Neurophysiol; 2000 Jun; 83(6):3366-76. PubMed ID: 10848555
[TBL] [Abstract][Full Text] [Related]
16. Modulation of inhibitory plasticity in basal ganglia output nuclei of patients with Parkinson's disease.
Milosevic L; Gramer R; Kim TH; Algarni M; Fasano A; Kalia SK; Hodaie M; Lozano AM; Popovic MR; Hutchison WD
Neurobiol Dis; 2019 Apr; 124():46-56. PubMed ID: 30391540
[TBL] [Abstract][Full Text] [Related]
17. GluR1 glutamate receptor subunit is regulated differentially in the primate basal ganglia following nigrostriatal dopamine denervation.
Betarbet R; Porter RH; Greenamyre JT
J Neurochem; 2000 Mar; 74(3):1166-74. PubMed ID: 10693949
[TBL] [Abstract][Full Text] [Related]
18. N-methyl-D-aspartate receptor blockade attenuates D1 dopamine receptor modulation of neuronal activity in rat substantia nigra.
Huang KX; Bergstrom DA; Ruskin DN; Walters JR
Synapse; 1998 Sep; 30(1):18-29. PubMed ID: 9704877
[TBL] [Abstract][Full Text] [Related]
19. Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate.
Brotchie JM; Mitchell IJ; Sambrook MA; Crossman AR
Mov Disord; 1991; 6(2):133-8. PubMed ID: 1647492
[TBL] [Abstract][Full Text] [Related]
20. The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism.
Wichmann T; Bergman H; DeLong MR
J Neurophysiol; 1994 Aug; 72(2):521-30. PubMed ID: 7983516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
